From May 3rd to 6th the American Association of Urology (AUA) hosted its national congress with the participation of 17,000 delegates. The congress is the most important annual event in the panorama of international urological events and offers the opportunity to discuss and present the medical and surgical innovations that will enter into clinical practice in the coming years.
The congress was also attended by the urology team of Humanitas headed by Professor Giorgio Guazzoni, with 10 presentations (4 podium presentations, one of which in plenary session, a video and 5 posters) dedicated both to cancer (kidney, bladder and prostate cancer) and to non-cancer disease (calculus).
Two awards to the urology team of Prof. Guazzoni
The Humanitas team also received two awards: Dr. Giovanni Lughezzani‘s poster entitled “Comparison Of Micro-Ultrasound And Multiparametric Mri Imaging For Prostate Cancer: An International Meta-Analysis” won the award for best communication of the session. The use of high-frequency ultrasound, currently available in Italy only at the Department of Urology of Humanitas, allows an early diagnosis of prostate cancer with an accuracy not inferior to magnetic nuclear resonance imaging.
The surgical technique video by Dr. Paolo Casale, presented by Dr. Nicolò Buffi, “Robot-Assisted Partial Nephrectomy: Techniques And Outcomes From The Transatlantic Robotic Nephron-Sparing Surgery (Trones) Study Group”, the result of a trans-Atlantic collaboration on partial robotic nephrectomy for the treatment of renal neoplasms, was selected by an American jury as the best video of the session.
A screening project for prostate cancer in healthy genetically mutated patients
Dr. Massimo Lazzeri presented in the plenary session a screening project for prostate cancer in healthy patients with Brca2 gene mutation entitled “Screening Of Brca2 Mutated Men For Detection Of Prostate Cancer: Preliminary Results From A National High Volume Cancer Centre”, for the early detection of prostate cancer in men with a specific mutation in their DNA. The Brca2 gene mutation is known, in particular, to be associated with an increased risk of breast cancer in women, but also plays an important role in men in both the case of male breast cancer and prostate cancer.
Bladder neoplasms: the results of a phase 1 drug trial
Dr. Rodolfo Hurle presented the results of a phase 1 drug trial of a drug for the intravesical treatment of bladder cancer: “A Phase 1 Safety Study Of Oncofid-P-B Administered For 12 Consecutive Weeks In Bcg Unresponsive/Intolerant Patients With Bladder Carcinoma In Situ (Cis): Preliminary Results”. The results obtained with this drug seem superior compared to those of other drugs at the end of the treatment. This is an important fact but it will have to be verified in the long run with the follow up.
Finally, a new device for the removal of kidney stones was presented in a poster by Dr. Alberto Saita: “In Vitro And In Vivo New Evidence For Flexor Vue Deflecting Endoscopic System Use: Optimization Of The Stone Free Rate (Sfr) After Rirs”.
“These are just some of the works of the Humanitas Urology of Prof. Guazzoni, again protagonist of an international congress. The collaboration with other Institutes and the strong teamwork between the different Operating Units of Humanitas have been important: a synergy that contributes to the success of our Institute. Moreover, the pride of our School of Specialities is the remarkable contribution that has been given by our Specialists in the preparation and presentation of some posters”, underlined Dr. Lazzeri and Dr. Nicolò Buffi.
